Bernd Doerken

3.0k total citations · 1 hit paper
19 papers, 2.1k citations indexed

About

Bernd Doerken is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Bernd Doerken has authored 19 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in Bernd Doerken's work include Lymphoma Diagnosis and Treatment (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Multiple and Secondary Primary Cancers (4 papers). Bernd Doerken is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Multiple and Secondary Primary Cancers (4 papers). Bernd Doerken collaborates with scholars based in Germany, Switzerland and Austria. Bernd Doerken's co-authors include Hanno Riess, Helmut Oettle, J. Fahlke, Ingo Schmidt‐Wolf, Karin Weigang-Koehler, Klaus Gellert, Marco Niedergethmann, P. Neuhaus, Wolf O. Bechstein and L. Roll and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Bernd Doerken

18 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

2007 1.8k citations Helmut Oettle, Stefan Post et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernd Doerken Germany	10	1.8k	729	672	661	509	19	2.1k
Katja Lindel Germany	22	708 0.4×	610 0.8×	466 0.7×	358 0.5×	374 0.7×	60	1.9k
Marianne Sinn Germany	15	1.6k 0.9×	673 0.9×	601 0.9×	435 0.7×	558 1.1×	49	1.8k
Robert Marsh United States	24	2.0k 1.1×	1.1k 1.5×	1.0k 1.5×	462 0.7×	490 1.0×	78	2.5k
Jerome C. Landry United States	34	1.8k 1.0×	1.5k 2.0×	1.3k 2.0×	378 0.6×	584 1.1×	115	3.3k
Ralf Wilkowski Germany	25	1.3k 0.7×	448 0.6×	533 0.8×	502 0.8×	524 1.0×	48	1.8k
Stefano Cereda Italy	21	1.1k 0.6×	564 0.8×	535 0.8×	311 0.5×	323 0.6×	53	1.5k
A. M. Cohen United States	19	1.9k 1.1×	1.2k 1.6×	522 0.8×	367 0.6×	311 0.6×	32	2.7k
Ming‐Chu Chang Taiwan	26	847 0.5×	854 1.2×	284 0.4×	367 0.6×	320 0.6×	69	1.9k
Francesco Minni Italy	30	1.7k 1.0×	1.4k 2.0×	887 1.3×	557 0.8×	272 0.5×	137	2.6k
C.J. van Groeningen Netherlands	22	1.1k 0.6×	1.0k 1.4×	590 0.9×	222 0.3×	208 0.4×	49	2.4k

Countries citing papers authored by Bernd Doerken

Since Specialization

Citations

This map shows the geographic impact of Bernd Doerken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Doerken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Doerken more than expected).

Fields of papers citing papers by Bernd Doerken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Doerken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Doerken. The network helps show where Bernd Doerken may publish in the future.

Co-authorship network of co-authors of Bernd Doerken

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Doerken. A scholar is included among the top collaborators of Bernd Doerken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Doerken. Bernd Doerken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Blau, Olga, Axel Nogai, Martin Schmidt‐Hieber, et al.. (2015). Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region. BMC Cancer. 15(1). 68–68. 41 indexed citations

Nogai, Hendrik, Stephan Hailfinger, Michael Grau, et al.. (2013). I{kappa}B-{zeta} controls the constitutive NF-{kappa}B target gene network and survival of ABC DLBCL. 4 indexed citations

Schwarz, Michaela, Theo D. Kim, Tristan Mirault, et al.. (2012). Elevated Risk of Peripheral Artery Occlusive Disease (PAOD) in Nilotinib Treated Chronic Phase Chronic Myeloid Leukemia (CML) Patients Assessed by Ankle-Brachial-Index (ABI) and Duplex Ultrasonography. Blood. 120(21). 914–914. 10 indexed citations

Hemmati, Philipp, Theis H. Terwey, Philipp le Coutre, et al.. (2011). Prognostic Impact of a Monosomal Karyotype in Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 17(2). S248–S249.

Pelzer, Uwe, Dirk Arnold, Jens Stieler, et al.. (2010). Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer. 10(1). 86–86. 58 indexed citations

Borchmann, Peter, Volker Diehl, Helen Goergen, et al.. (2009). Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.. Blood. 114(22). 717–717. 9 indexed citations

Trappe, Ralf Ulrich, Carl Hinrichs, Nina Babel, et al.. (2009). Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression. American Journal of Transplantation. 9(10). 2331–2337. 36 indexed citations

Engert, Andreas, Volker Diehl, Annette Pluetschow, et al.. (2009). Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10. Study Supported by the Deutsche Krebshilfe and in Part by the Competence Network Malignant Lymphoma.. Blood. 114(22). 716–716. 6 indexed citations

Neuburger, Stefan, Gero Massenkeil, Michael Seibold, et al.. (2008). Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transplant Infectious Disease. 10(4). 290–293. 23 indexed citations

10.

Oettle, Helmut, Stefan Post, P. Neuhaus, et al.. (2007). Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. JAMA. 297(3). 267–267. 1754 indexed citations breakdown →

11.

Diehl, Volker, Corinne Brillant, Andreas Engert, et al.. (2005). HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). Journal of Clinical Oncology. 23(16_suppl). 6506–6506. 34 indexed citations

12.

Engert, Andreas, Annette Pluetschow, Hans Theodor Eich, et al.. (2005). Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).. Blood. 106(11). 2673–2673. 17 indexed citations

13.

Diehl, Volker, Corinne Brillant, Andreas Engert, et al.. (2005). Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.. Blood. 106(11). 816–816. 15 indexed citations

14.

Diehl, Volker, Corinne Brillant, Andreas Engert, et al.. (2004). Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.. Blood. 104(11). 1307–1307. 9 indexed citations

15.

Diehl, Volker, Corinne Brillant, Andreas Engert, et al.. (2004). Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG.. Blood. 104(11). 1308–1308. 8 indexed citations

16.

Zeidler, Kristin, Petra Reinke, Erik A.M. Verschuuren, et al.. (2002). Monotherapy with the anti-CD20 antibody rituximab (ritux) in patients with post-transplant lympho-proliferative disease (PTLD). Results of a multicentre phase II study.. Data Archiving and Networked Services (DANS). 2 indexed citations

17.

Waßmuth, Ralf, Suzanne Lentzsch, Uta Erdbrüegger, et al.. (2001). Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study. American Heart Journal. 141(6). 1007–1013. 115 indexed citations

18.

Knauf, Wolfgang, et al.. (1991). Mediastinal Clear Cell Lymphoma—A Distinct Entity of B-Cell Derived Lymphoma as Shown by Immunotyping and Analysis of Gene Rearrangements. Leukemia & lymphoma. 6(1). 49–52. 5 indexed citations

19.

Heilig, B., et al.. (1986). Monoclonal antibodies against human thyroglobulin properties and their use in an immunoradiometric assay. 32(4). 85–90. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact